Endothelial differntiation gene 6-like g protein coupled receptor
OwnerKevin Bacon, Jeffrey Encinasinventors
Life of this patent
Estimating the term…
Abstract
Disclosed are novel nucleic acid and amino acid sequences of an endothelial differentiation gene 6 (EDG6)-like G protein coupled receptor. Reagents that bind to EDG6-like receptor gene products can be used to treat conditions involving inflammatory processes, such as allergy, asthma, autoinamune diseases, and other chronic inflammatory diseases where an over-activation or prolongation of the activation of the immune system causes damage to tissues.
Claims79
An isolated polynucleotide encoding a EDG6-LIKE GPCR polypeptide and being selected from the group consisting of:
- a) a polynucleotide encoding a EDG6-LIKE GPCR polypeptide comprising an amino acid sequence selected from the group consisting of:
- amino acid sequences which are at least about 25% identical to the amino acid sequence shown in SEQ ID NO:
- 1;
- an the amino acid sequence shown in SEQ ID NO:
- 1.
- b) a polynucleotide comprising the sequence of SEQ ID NO:
- 2;
- c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
- d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code;
- and
- e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d).
A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 1
An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 1
A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 1.
A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 1.
A fuision protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:
- 1.
A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 1, comprising the steps of:
- culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed;
- and isolating the polypeptide.
A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 1, comprising the steps of:
- hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO:
- 2 to nucleic acid material of a biological sample, thereby forming a hybridization complex;
- and detecting the hybridization complex.
A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 1, comprising the steps of:
- contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
- and detecting the reagent-polypeptide complex.
A method of screening for agents which can regulate the activity of a EDG6- LIKE GPCR protein, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 25% identical to the amino acid sequence shown in SEQ ID NO:
- 1 and (2) the amino acid sequence shown in SEQ ID NO:
- 1;
- and
- detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the EDG6-LIKE GPCR protein.
A method of screening for agents which regulate an activity of a human human EDG6-LIKE GPCR protein, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 25% identical to the amino acid sequence shown in SEQ ID NO:
- 1 and (2) the amino acid sequence shown in SEQ ID NO:
- 1;
- and
- detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human EDG6-LIKE GPCR protein, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human EDG6-LIKE GPCR protein.
A method of screening for agents which regulate an activity of a human EDG6-LIKE GPCR protein, comprising the steps of:
- contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO:
- 2;
- and detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human EDG6-LIKE GPCR protein.
A method of reducing activity of a human EDG6-LIKE GPCR protein, comprising the step of:
- contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:
- 2, whereby the activity of a human EDG6-LIKE GPCR protein is reduced.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO;
- 1;
- and a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:
- 2;
- and a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 1;
- and a pharmaceutically acceptable carrier.
A method of treating EDG6-LIKE GPCR, comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that inhibits a function of a human EDG6-LIKE GPCR protein, whereby symptoms of the EDG6-LIKE GPCR are ameliorated.
A method of treating a EDG6-LIKE GPCR disorder, comprising the step of-
- administering to a patient in need thereof a therapeutically effective dose of a reagent that inhibits a fuinction of a human EDG6-LIKE GPCR protein, whereby symptoms of the EDG6-LIKE GPCR disorder are ameliorated.
Dependencies are inferred from the claim text.